AKT1 and melanoma: As a potential mechanism of acquired resistance, it has been reported that mutation-specific ctDNA assays allow early detection of the onset of NRAS mutation in patients treated with BRAFi, other than mutations in MAP2K1, AKT1, and PIK3CA in melanoma patients showing treatment resistance [223,224,225].